Does rivaroxaban reduce the incidence of venous thromboembolism or death due to venous thromboembolism in high-risk ambulatory patients with cancer?
Rivaroxaban did not significantly reduce the 180-day incidence of VTE or VTE-related death in high-risk ambulatory cancer patients, though events were lower during the active intervention period.
In high-risk ambulatory patients with cancer, treatment with rivaroxaban did not result in a significantly lower incidence of venous thromboembolism or death due to venous thromboembolism in the 180-day trial period. During the intervention period, rivaroxaban led to a substantially lower incidence of such events, with a low incidence of major bleeding. (Funded by Janssen and others; CASSINI ClinicalTrials.gov number, NCT02555878.).
Khorana et al. (Wed,) studied this question.